Idebenone
- Generic Name
- Idebenone
- Brand Names
- Raxone
- Drug Type
- Small Molecule
- Chemical Formula
- C19H30O5
- CAS Number
- 58186-27-9
- Unique Ingredient Identifier
- HB6PN45W4J
- Background
Idebenone is a synthetic analogue of ubiquinone (also known as Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC). It has been proposed that by interacting with the ETC, idebenone increases ATP production required for mitochondrial function, reduces free radicals, inhibits lipid peroxidation, and consequentl...
- Indication
Idebenone is indicated for use by the European Medicines Agency (EMA) for the treatment of visual impairment in adolescent and adult patients with
Leber’s Hereditary Optic Neuropathy (LHON). It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada .
- Associated Conditions
- Alzheimer's Disease (AD), Leber’s hereditary optic neuropathy
- Associated Therapies
- -
Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Target Recruit Count
- 64
- Registration Number
- NCT05931029
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital，Sun Yat-sen University，Guangzhou 510300，China, Guangzhou, Guangdong, China
Safety and Efficacy of Oral Idebenone for Preventive Treatment of Migraine in Adult Migraine Patients
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 900
- Registration Number
- NCT05411978
- Locations
- 🇨🇳
Yonggang Wang, Beijing, China
Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT04669158
- Locations
- 🇺🇸
Digestive Health Center, Stanford University, Redwood City, California, United States
🇺🇸Stanford University, Stanford, California, United States
A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 142
- Registration Number
- NCT04534023
- Locations
- 🇨🇳
Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2021-07-16
- Target Recruit Count
- 180
- Registration Number
- NCT04152655
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Symptomatic Therapy for Patients With Huntington's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-04-02
- Target Recruit Count
- 60
- Registration Number
- NCT04071639
- Locations
- 🇨🇳
Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Santhera Pharmaceuticals
- Registration Number
- NCT03433807
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Study to Assess the Efficacy and Safety of Raxone in LHON Patients
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT02774005
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
🇪🇸Institut Catala de Retina, Barcelona, Spain
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Spain
Post Authorisation Safety Study With Raxone in LHON Patients
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT02771379
- Locations
- 🇮🇹
Ospedale San Raffaele, Milano, Italy
🇩🇪Universitaetsklinikum Essen, Essen, Germany
🇫🇷CHU Amiens - Centre Saint Victor, Amiens, Somme, France
Idebenone for Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2021-05-19
- Target Recruit Count
- 61
- Registration Number
- NCT01854359
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.